[{"id":"79725e7c-a938-4a9e-b556-bf960936b158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618641","created_at":"2021-09-17T01:53:43.496Z","updated_at":"2025-02-25T16:31:32.025Z","phase":"Phase 2","brief_title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","source_id_and_acronym":"NCT03618641","lead_sponsor":"Diwakar Davar","biomarkers":" CD8 • CD4 • SOX10","pipe":"","alterations":" ","tags":["CD8 • CD4 • SOX10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/08/2018","start_date":" 08/08/2018","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-07"},{"id":"93546d33-d260-437a-9cd5-b7629d9d588d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708418","created_at":"2023-04-01T19:06:08.459Z","updated_at":"2025-02-25T16:38:10.265Z","phase":"Phase 2","brief_title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","source_id_and_acronym":"NCT04708418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"6724b39f-08dd-46d5-950d-1b4b715f5e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT05061017","created_at":"2021-09-29T11:53:50.927Z","updated_at":"2024-07-02T16:34:58.857Z","phase":"Phase 2","brief_title":"Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)","source_id_and_acronym":"NCT05061017","lead_sponsor":"Diwakar Davar","biomarkers":" KRAS • BRAF • ALK • MET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • cyclophosphamide intravenous • pixatimod (PG545)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 03/18/2024","study_completion_date":" 03/18/2024","last_update_posted":"2024-06-04"},{"id":"e0dcb469-2253-48cc-bf9a-3c24a50a8266","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401995","created_at":"2022-04-05T20:52:55.878Z","updated_at":"2024-07-02T16:35:06.245Z","phase":"Phase 2","brief_title":"Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab","source_id_and_acronym":"NCT04401995","lead_sponsor":"Diwakar Davar","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 07/30/2028","primary_completion_date":" 07/30/2028","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2024-05-03"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"c7d821cf-1074-4b09-aa9f-2289017bf8ff","acronym":"CMP-001-007","url":"https://clinicaltrials.gov/study/NCT04633278","created_at":"2021-01-19T20:36:57.016Z","updated_at":"2024-07-02T16:35:21.076Z","phase":"Phase 2","brief_title":"CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04633278 - CMP-001-007","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 01/19/2024","primary_completion_date":" 01/19/2024","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2024-02-02"},{"id":"b7659aa4-c8c0-4419-bda6-e8c9eced4212","acronym":"PERIO-02","url":"https://clinicaltrials.gov/study/NCT05220722","created_at":"2023-07-27T22:08:59.303Z","updated_at":"2025-02-25T16:32:45.067Z","phase":"Phase 1/2","brief_title":"Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors","source_id_and_acronym":"NCT05220722 - PERIO-02","lead_sponsor":"TriSalus Life Sciences, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • nelitolimod (SD-101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-12-25"},{"id":"ab666c9a-6427-43ed-a474-52d69624f062","acronym":"","url":"https://clinicaltrials.gov/study/NCT00292045","created_at":"2021-01-27T22:52:15.081Z","updated_at":"2024-07-02T16:35:34.747Z","phase":"Phase 1","brief_title":"Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer","source_id_and_acronym":"NCT00292045","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B","pipe":"","alterations":" ","tags":["CD8 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/27/2004","start_date":" 10/27/2004","primary_txt":" Primary completion: 01/09/2006","primary_completion_date":" 01/09/2006","study_txt":" Completion: 01/09/2006","study_completion_date":" 01/09/2006","last_update_posted":"2023-10-04"},{"id":"acb324c0-7ea9-4e70-8f73-9c5486bc513d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199836","created_at":"2021-01-18T00:40:44.608Z","updated_at":"2024-07-02T16:36:02.794Z","phase":"Phase 1","brief_title":"A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.","source_id_and_acronym":"NCT00199836","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/03/2003","start_date":" 09/03/2003","primary_txt":" Primary completion: 09/05/2005","primary_completion_date":" 09/05/2005","study_txt":" Completion: 06/06/2006","study_completion_date":" 06/06/2006","last_update_posted":"2022-10-10"},{"id":"cd953313-4922-4eb7-86f4-86fd680fb3b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299728","created_at":"2021-01-18T01:01:31.071Z","updated_at":"2024-07-02T16:36:02.802Z","phase":"Phase 1","brief_title":"NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors","source_id_and_acronym":"NCT00299728","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression • CTAG2 expression","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/21/2006","start_date":" 03/21/2006","primary_txt":" Primary completion: 10/10/2006","primary_completion_date":" 10/10/2006","study_txt":" Completion: 01/10/2014","study_completion_date":" 01/10/2014","last_update_posted":"2022-10-10"},{"id":"e5a8e0c7-3d27-4fa1-bebf-518326e168c8","acronym":"CMP-001-003","url":"https://clinicaltrials.gov/study/NCT03438318","created_at":"2021-01-18T16:56:58.252Z","updated_at":"2024-07-02T16:36:06.118Z","phase":"Phase 1b","brief_title":"Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03438318 - CMP-001-003","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • vidutolimod (CMP-001) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 12/11/2019","primary_completion_date":" 12/11/2019","study_txt":" Completion: 12/11/2019","study_completion_date":" 12/11/2019","last_update_posted":"2022-08-03"},{"id":"f1f6b8e5-c84d-462b-b982-ad3644c8b216","acronym":"ILLUMINATE 204","url":"https://clinicaltrials.gov/study/NCT02644967","created_at":"2021-01-18T12:52:09.133Z","updated_at":"2024-07-02T16:36:06.121Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02644967 - ILLUMINATE 204","lead_sponsor":"Idera Pharmaceuticals, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • tilsotolimod (IMO-2125)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2022-08-03"},{"id":"5bd424f1-c902-443d-b96a-53719bab44f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04807192","created_at":"2021-03-19T15:59:09.329Z","updated_at":"2024-07-02T16:36:28.123Z","phase":"Phase 2","brief_title":"CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT04807192","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vidutolimod (CMP-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-07-09"},{"id":"90fb6027-621c-4dc6-9ea8-cc3e46aa43e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00819806","created_at":"2021-02-16T02:52:12.218Z","updated_at":"2024-07-02T16:37:19.374Z","phase":"Phase 1","brief_title":"CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors","source_id_and_acronym":"NCT00819806","lead_sponsor":"Hassane M. Zarour, MD","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Promune (agatolimod) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2017-07-31"}]